Abstract 364P
Background
Lung cancer treatment gets on the stage of precision medicine. Histopathological classification of lung cancer is crucial in determining optimum treatment. Artificial intelligence (AI) models have been widely shown to be useful in pathological diagnosis and we previously established a reliable AI model to detect the presence of lung cancer on whole slide images (WSIs). However, AI models for the differentiation of major histological types of lung cancer, such as adenocarcinoma (ADC), squamous cell carcinoma (SCC) and small-cell lung cancer (SCLC), are yet to be established.
Methods
We trained a convolution neural network (CNN) based on the EfficientNet-B1 architecture to classify ADC, SCC, SCLC, and non-neoplastic lesion from biopsy specimen WSIs (70, 23, 12 and 171 specimens with ADC, SCC, SCLC and non-neoplastic lesion, respectively) using a training dataset of 276 images of which 60 were reserved for validation. The WSIs were manually annotated by pathologists by drawing around the regions that contain each subtype. We used a transfer learning approach, in which the starting weights were obtained from a pre-trained model on ImageNet. The model was then trained on our dataset using a supervised learning approach. To classify a WSI, the model was applied in a sliding window fashion with an input tile size of 224x224 and a stride of 128 on a magnification of x10. The maximum probability was then used as a WSI diagnosis.
Results
We evaluated our model on a total of 533 WSIs that only had WSI diagnoses. The model achieved a Receiver Operator Curve Area Under the Curves of 0.888 (CI 0.872-0.9075), 0.8913 (CI 0.8596-0.9221), 0.9526 (CI 0.9276-0.9646) for ADC, SCC, and SCLC, respectively.
Conclusions
The obtained results on a large test set are a promising first step towards developing a model for the classification of lung cancer. Our model was only trained on a small dataset of 276 WSIs; however, we hope that the model would be further improved with the collection of additional annotated WSIs for training. Having a high performing model could help reduce the burden on pathologists and be useful for the decision of optimum treatment strategies, such as molecular-targeted therapy, immunotherapy and chemotherapy, according to the histological types of lung cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
359P - The role of adjuvant targeted therapy for postoperative EGFR mutant non-small cell lung cancer: A network meta-analysis
Presenter: Guang Ling Jie
Session: e-Poster Display Session
360P - Number of lymph nodes examined was not an independent risk factor for the survival of patients with stage IA1-2 lung adenocarcinoma undergoing sublobar resection
Presenter: Zhenbin Qiu
Session: e-Poster Display Session
361P - Radiomic model predicting radiological response after thoracic stereotactic body radiotherapy regardless of tumor histology and staging
Presenter: Ben Man Fei Cheung
Session: e-Poster Display Session
362P - Integrative and comparative genomic analysis and immune microenvironment features of lung cancer patients with tuberculosis
Presenter: Xiaoling Xu
Session: e-Poster Display Session
363P - Genetic predisposition for pre-invasive lung adenocarcinoma manifesting as ground-glass nodules with family history of lung cancer
Presenter: Rui Fu
Session: e-Poster Display Session
365P - Utilization of on-site pathology evaluation for lung cancer diagnosis in the Philippines’ National University Hospital
Presenter: Rich Ericson King
Session: e-Poster Display Session
367P - Detection of epidermal growth factor receptor mutations (EGFR-mut) from cell-free DNA in pleural effusion (PE-DNA) of patients with non-small cell lung cancer (NSCLC)
Presenter: Kirsty Lee
Session: e-Poster Display Session
368P - Real-world characteristics, treatment, and outcomes of stage III non-small cell lung cancer in Japan: SOLUTION study
Presenter: Haruyasu Murakami
Session: e-Poster Display Session
369P - The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer
Presenter: Long Jiang
Session: e-Poster Display Session
371P - Real-world insights into treatment patterns and outcomes in stage III non-small cell lung cancer (NSCLC): KINDLE study India analysis
Presenter: Kumar Prabhash
Session: e-Poster Display Session